1. . Бойцов С. А. Механизмы снижения смертности от ишемической болезни сердца в разных странах мира. Профилактическая медицина. 2013;16(5):9-19.
2. McAlister FA, Oreopoulos A, Norris CM, et al. Exploring the treatment-risk paradox in coronary disease. Arch Intern Med. 2007;167(10):1019-25. https://doi.org/10.1001/archinte.167.10.1019.
3. Brar A, Santana JM, Salifu MO, et al. Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. In: McFarlane SI ed. Dyslipidemia. 1st ed. New York: IntechOpen., 2019;1-25. https://doi.org/10.5772/intechopen.82831. ISBN: 978-1-83968-004-5.
4. Berthold HK, Gouni-Berthold I. Lipid-lowering Drug Therapy in Elderly Patients. Curr Pharm Des. 2011;17(9):877-93. https://doi.org/10.2174/138161211795428803.
5. Orimo H, Ito H, Suzuki T, et al. Reviewing the definition of “elderly” Geriatr Gerontol Int. 2006;6(3): 149-58. https://doi.org/10.1111/j.1447-0594.2006.00341.x.
6. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-350. https://doi.org/10.1161/CIR.0000000000000625.
7. Fitilev SB, Dimitrova DA, Shkrebneva II, et al. Secondary prevention of cardiovascular diseases among patients of different age groups with a history of myocardial infarction by the example of outpatient cardiology institution. Ration Pharmacother Cardiol. 2017; 13(3):317-22. https://doi.org/10.20996/1819-6446-2017-13-3-317-322.
8. De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135-46. https://doi.org/10.1016/j.atherosclerosis.2019.03.014.
9. Jepma P, Jorstad HT, Snaterse M, et al. Lifestyle modification in older versus younger patients with coronary artery disease. Heart. 2020;106:1066-72. https://doi.org/10.1136/heartjnl-2019-316056.
10. Phrommintikul A, Krittayaphong R, Wongcharoen W, et al. Management and risk factor control of coronary artery disease in elderly versus nonelderly: A multicenter registry. J Geriatr Cardiol. 2016;13(12):954-9. https://doi.org/10.11909/j.issn.1671-5411.2016.12.002.
11. Xia TL, Huang FY, Li YM, et al. The impact of age on the implementation of evidence-based medications in patients with coronary artery disease and its prognostic significance: A retrospective cohort study. BMC Public Health. 2018;18(1):1-10. https://doi.org/10.1186/s12889-018-5049-x.
12. Ponce OJ, Larrea-Mantilla L, Hemmingsen B, et al. Lipid-Lowering Agents in Older Individuals: A Systematic Review and MetaAnalysis of Randomized Clinical Trials. J Clin Endocrinol Metab. 2019;104(5):1585-94. https://doi.org/10.1210/jc.2019-00195.
13. Armitage J, Baigent C, Barnes E, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-15. https://doi.org/10.1016/S0140-6736( 18)31942-1.
14. Munkhaugen J, Sverre E, Peersen K, et al. Is the novel LDL-cholesterol goal <1.4 mmol/L achievable without a PCSK9 27 inhibitor in a chronic coronary population from clinical practice? Eur Prev Cardiol. 2020;204748732092318. https://doi.org/10.1177/2047487320923187
15. Rallidis LS. The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients. Atherosclerosis. 2020;292:231-3. https://doi.org/10.1016/j.atherosclerosis.2019.11.009.
16. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41 (1): 111-88. https://doi.org/10.1093/eurheartj/ehz455.
17. Ruscica M, Macchi C, Pavanello C, et al. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33-40. https://doi.org/10.1016/j.ejim.201712.011.
18. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25-37 https://doi.org/10.1080/14740338.2018.1394455.
19. Dias BM, Dos Santos FS, Reis AMM. Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: Cross-sectional study. Sao Paulo Med J. 2019;137(4):369-78. https://doi.org/10.1590/1516-3180.2019.013405072019.
20. Ежов М. В., Сергиенко И. В., Аронов Д. М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;(3):5-22.
21. Thai M, Reeve E, Hilmer SN, et al. Prevalence of statin-drug interactions in older people: A systematic review. Eur J Clin Pharmacol. 2016;72(5):513-21. https://doi.org/10.1007/s00228-016-2011-7
22. Wang YC, Hsieh TC, Chou CL, et al. Risks of adverse events following coprescription of statins and calcium channel blockers: A nationwide population-based study. Medicine (Baltimore). 2016;95(2):e2487 https://doi.org/10.1097/MD.0000000000002487.
23. Tokgozoglu L, Zamorano JL. Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. Drugs Context. 2020;9(2020-4-4):1-11. https://doi.org/10.7573/dic.2020-4-4.
24. Ministry of Health of Russia. Clinical recommendations “Stable coronary heart disease”. 2016. (In Russ.) Министерство здравоохранения Российской Федерации. Клинические рекомендации “Стабильная ишемическая болезнь сердца”. 2016. http://webmed.irkutsk.ru/doc/pdf/fedcad.pdf.
25. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. https://doi.org/10.1093/eurheartj/ehu038.
26. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25:4076. https://doi.org/10.15829/1560-4071-2020-4076.
27. Knuuti J. 2019 Рекомендации ESC по диагностике и лечению хронического коронарного синдрома. Российский кардиологический журнал. 2020;25(2):3757. https://doi.org/10.15829/1560-4071-2020-2-3757.
28. Zyryanov SK, Fitilev SB, Vozzhaev AV, Shkrebniova II, Shindryaeva NN, Klyuev DA, StepanyanLN, Landyshev NN, Voronko YG (2020). Medication adherence in patients with stable coronary artery disease in primary care. Research Results in Pharmacology 6(2):97-103. https://doi.org/10.3897/rrpharmacology.6.54130